Q2 EPS Forecast for iTeos Therapeutics Lifted by Analyst

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Stock analysts at HC Wainwright upped their Q2 2025 earnings per share estimates for iTeos Therapeutics in a research note issued on Tuesday, April 29th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.17) per share for the quarter, up from their prior estimate of ($1.44). HC Wainwright currently has a "Buy" rating and a $46.00 target price on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for iTeos Therapeutics' Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($1.46) EPS, FY2025 earnings at ($4.89) EPS, FY2026 earnings at ($5.44) EPS, FY2027 earnings at ($3.31) EPS and FY2028 earnings at ($0.70) EPS.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14.

Other analysts have also issued reports about the company. Wells Fargo & Company lowered their price objective on iTeos Therapeutics from $17.00 to $16.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Wedbush reissued an "outperform" rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating for the company in a report on Thursday, March 6th.

iTeos Therapeutics Stock Down 7.6 %

Shares of ITOS traded down $0.59 during midday trading on Friday, hitting $7.18. The company had a trading volume of 211,470 shares, compared to its average volume of 486,152. The stock has a market cap of $274.81 million, a price-to-earnings ratio of -2.28 and a beta of 1.39. The company's 50 day moving average price is $6.59 and its 200 day moving average price is $7.52. iTeos Therapeutics has a 52 week low of $4.80 and a 52 week high of $18.75.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC boosted its holdings in shares of iTeos Therapeutics by 12.2% during the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company's stock valued at $106,000 after acquiring an additional 1,508 shares during the period. Wells Fargo & Company MN boosted its stake in iTeos Therapeutics by 16.9% during the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock valued at $128,000 after purchasing an additional 2,402 shares during the period. Virtus ETF Advisers LLC grew its position in iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock worth $69,000 after purchasing an additional 3,293 shares during the last quarter. Empowered Funds LLC increased its stake in shares of iTeos Therapeutics by 5.0% in the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company's stock valued at $530,000 after purchasing an additional 3,305 shares during the period. Finally, Bridgeway Capital Management LLC raised its holdings in shares of iTeos Therapeutics by 5.0% during the fourth quarter. Bridgeway Capital Management LLC now owns 69,072 shares of the company's stock valued at $530,000 after buying an additional 3,305 shares during the last quarter. 97.16% of the stock is currently owned by institutional investors.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.